AbbVie hits go on $1B re-upped Calico deal as the Google life science spin-out continues I-O, neuro push

Seven years ago, AbbVie penned an early-stage deal with Google/Alphabet’s life sciences division Calico: The pair have clearly enjoyed their time together, as they are penning a second extension for that collab.

This deal first saw pen hit paper all the way back in 2014 and focused on age-related diseases, including neurodegeneration and cancer. Back in 2018, the pair signed their first extension to the collab, putting in an extra $1 billion to keep it going.

It ’s a case of déjà vu today as another $1 billion (split 50-50 between the two) goes into the pot, and another extension, bringing the collab another three years from 2022, now up to 2025. Under the terms, Calico is responsible for research and early development until that date and will push on the collab projects into phase 2a through to the next decade.